M. Napolitano
Abstract
COVID19 has dramatically modified several aspects of medical care, this is particularly true for patients affected by a chronic, rare disease like haemophilia A and B. Several issues and concerns have been raised during the course of the current pandemic, which include: the relations between physicians and patients; the management of replacement therapies and prophylaxis, with the prompt development of ad hoc recommendations by National and International Societies involved in haemophilia care; advice about vaccines against Sars-CoV2 and their administration; the development of telemedicine and its widespread use. The current presentation describes each of these specific aspects, currently still involving the “new and next future” management of haemophilia.
(»Download here full PDF version)
